Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Antimicrobial Susceptibility Testing of 59 Strains of Campylobacter fetus subsp. fetus

Carole Tremblay, Christiane Gaudreau
Carole Tremblay
Département de Microbiologie Médicale et Infectiologie, Pavillon St-Luc, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada H2X 3J4
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Gaudreau
Département de Microbiologie Médicale et Infectiologie, Pavillon St-Luc, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada H2X 3J4
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.42.7.1847
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The susceptibilities of 59 Campylobacter fetus subsp.fetus isolates to eight antibiotics were studied by the agar dilution, E-test, and disk diffusion methods. None of the isolates were β-lactamase producers. All were susceptible to ampicillin, gentamicin, imipenem, and meropenem as determined by the three methods, with MICs at which 90% of the isolates are inhibited (MIC90s) (determined by agar dilution) of 2, 1, ≤0.06, and 0.12 μg/ml, respectively. Twenty-seven percent of the isolates were resistant to tetracycline, with complete agreement between the agar dilution and disk diffusion results. The MIC90s determined by agar dilution were 2 μg/ml for erythromycin, 1 μg/ml for ciprofloxacin, and 8 μg/ml for cefotaxime.

Campylobacter fetussubsp. fetus is a rare human pathogen that causes extraintestinal infections and bacteremia, mainly in patients with serious underlying conditions or immunosuppression (2, 22, 25). Systemic C. fetus subsp. fetusinfections often require prolonged parenteral therapy with one or two antibiotics, and the prognosis may be poor for the compromised host (2). There is no standardized susceptibility testing method for this organism (19).

The objectives of this study were to determine β-lactamase production of 59 strains of C. fetus subsp. fetus isolated in Québec, Canada, and the antimicrobial susceptibility patterns of those strains against eight antibiotics. Three methods of susceptibility testing were compared: agar dilution, disk diffusion, and the E test.

Fifty-nine strains were tested by the agar dilution and the disk diffusion tests with eight antibiotics, 17 of which strains were isolated in our institution and 42 of which were provided by the Laboratoire de Santé Publique du Québec. Of the 59 strains, 30 were also tested by the E test for four of the antibiotics. All strains were previously identified as C. fetus subsp.fetus based on standard criteria and methodology (19).

The antibiotics used were ampicillin, gentamicin, erythromycin, tetracycline, cefotaxime, ciprofloxacin (all from Sigma Chemical Co., St. Louis, Mo.), imipenem (Merck Sharp & Dohme, West Point, Pa.), and meropenem (Zeneca Pharma Inc., Mississauga, Ontario, Canada).

Suspensions of 24- to 48-h blood agar cultures were adjusted to a 0.5 McFarland turbidity standard in Mueller-Hinton broth (BBL Microbiology Systems) for the disk diffusion and E test methods and diluted 1:10 for agar dilution. A final inoculum of 104 CFU was applied to unsupplemented Mueller-Hinton plates (BBL) for agar dilution with a Cathra 3-mm replicator. The antibiotic concentrations ranged from 0.06 to 128 μg/ml, and a control plate without antibiotic was inoculated at the beginning of the procedure. All plates were incubated for 48 h at 35°C under microaerophilic conditions (about 5% O2, 10% CO2, and 85% N2) with gas generator envelopes (Difco).

A standard method of inoculation was used for disk diffusion and the E test (21) with the same medium and incubation conditions as for agar dilution.

For agar dilution, the endpoint was taken as the concentration that resulted in complete inhibition of visible growth. For the E test, the MIC was read at the point of intersection between the inhibition ellipse and the E-test strip. For the disk diffusion test, the antibiotic concentrations were chosen according to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (21). The zone diameters were measured with slipping calipers. NCCLS susceptibility criteria were used to interpret the results for aerobic organisms (20, 21), since no such criteria are available for C. fetus subsp. fetus.

The following quality control strains were used: Staphylococcus aureus ATCC 29213, S. aureus ATCC 25923,Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853.

A nitrocefin solution method in microwells was used for β-lactamase detection, as previously described by Lachance et al. (13).S. aureus ATCC 29213 and S. aureus ATCC 25923 were used as positive and negative controls, respectively. ThreeCampylobacter jejuni strains in which β-lactamase had previously been isolated and characterized were also used as positive controls (14).

All strains were β-lactamase negative. The percentages of susceptible strains determined by the three methods are indicated in Table1 with the corresponding disk diameters for the susceptible organisms. MIC ranges, the MICs at which 50% of the isolates are inhibited (MIC50s) and MIC90s determined by the agar dilution and E-test methods are also indicated. All isolates were susceptible to ampicillin, gentamicin, imipenem, and meropenem by the three methods. The lowest MICs were obtained with gentamicin, imipenem, and meropenem.

View this table:
  • View inline
  • View popup
Table 1.

Susceptibilities of 59 strains of C. fetussubsp. fetus as determined by agar dilution, disk diffusion, or E test

There was complete agreement between the agar dilution and disk diffusion test results for tetracycline: 27% of isolates were resistant and 73% were susceptible by both methods.

The percentages of intermediate MICs were 61% for erythromycin, 2% for ciprofloxacin, and 10% for cefotaxime by the agar dilution method. When agar dilution and disk diffusion were compared, minor error rates were 61% with erythromycin, 12% with cefotaxime, and 2% with ciprofloxacin. There was no major or very major error with any of the antibiotics.

Overall agreement of MICs ±1 log2 dilution between the agar dilution and the E-test method (data not shown) was 100% with gentamicin and imipenem, 98% with meropenem, and 90% with ampicillin. An important discrepancy was seen with cefotaxime, to which none of the 30 strains were susceptible by the E test, with 10 and 90% being intermediate and resistant, respectively (compared with 90% of strains being susceptible and 10% being intermediate by the agar dilution method). This was not observed with the control strains, for which MICs were within the expected limits under identical testing conditions. Also, such a difference was not observed between the agar dilution and the disk diffusion tests, whose results were more concordant (90% susceptible by agar dilution and 84% susceptible by disk diffusion).

Few studies of C. fetus subsp. fetussusceptibility have been published over the past 20 years, and in those few, a wide variety of inocula and media have been used (3-6, 9, 11, 12, 17, 26), mostly on a small number of strains (average, 13; range, 2 to 30). Interstudy comparison has therefore been difficult.

Fliegelman et al. (6) and Spelhaug et al. (26) evaluated β-lactamase production and found no positive strains (of a combined total of 34 for both studies), which is in agreement with our results. None of our isolates were resistant to ampicillin. The MIC range obtained was comparable to those in the literature describing tests in which a similar inoculum was used (6, 9, 17, 26). A small number of resistant strains were reported in studies (3-5) with inocula with McFarland standards ranging from 1 to 3, but none of these studies reported β-lactamase testing. Treatment failures have been reported in a recent review (16), but patients described in that work suffered from severe endovasculitis and associated conditions. Ampicillin has been considered a reasonable choice whenever susceptibility testing could be done (2, 7). In two studies (17, 26), its bactericidal activity was considered superior to those of expanded-spectrum cephalosporins, such as cefotaxime, but inferior to those of gentamicin and imipenem.

Similar to our findings, gentamicin (3-6, 9, 12, 17, 26), imipenem (17, 26), and meropenem (12) had the lowest MICs in previous studies, and no resistance has yet been reported. Gentamicin and imipenem are considered the preferred treatments for severe systemic infections (2, 9, 18), and imipenem was suggested as the first-choice agent for dealing with central nervous system infections (17).

Our results showed a high percentage of intermediate MICs of erythromycin. This was also previously observed (4-6, 9, 12) with C. fetus subsp. fetus. Several therapeutic failures or relapses were reported with that agent, sometimes with strains initially shown to be sensitive, and it is no longer a recommended treatment for systemic C. fetus subsp.fetus infections (2, 7, 16, 23).

Reported resistance to tetracycline has been low, occurring in one or two strains and in only one study (9), in contrast with our finding that 27% of our isolates were resistant to tetracycline.C. jejuni and Campylobacter coli tetracycline resistance mediated by a plasmid with demonstrated transmissibility from C. jejuni to C. fetus (29) has been described by Taylor et al. (27, 29).

Few of the reviewed studies reported ciprofloxacin resistance (9, 12, 24). C. fetus subsp. fetus quinolone resistance mediated by a mutation on the gyrase gene has been described (28). Two cases of bacteremic infection with quinolone-resistant C. fetus subsp. fetus in immunosuppressed patients who had prior contact with the antibiotic have been reported (15).

While a majority of our isolates were sensitive to cefotaxime by the disk diffusion and the agar dilution methods, the MIC50s and MIC90s for the isolates were at the susceptibility limit of 8 μg/ml. Intermediate MIC90s of cefotaxime were found in five studies (9, 11, 12, 17, 26), and its bactericidal activity was generally lower than those of ampicillin, gentamicin, and imipenem (17, 26). Although expanded-spectrum cephalosporins were mentioned as an alternative choice in treating C. fetus subsp. fetus systemic infections (2), we tend to believe that cefotaxime should be used with caution, keeping in mind that its activity could be only moderate. E-test susceptibility testing for that agent seems unreliable with C. fetus subsp. fetus, and we do not recommend its use until further study can be done.

Overall agreement among the three testing methods with the antimicrobial agents most often used clinically in treating C. fetus subsp. fetus infections (ampicillin, gentamicin, imipenem, and meropenem) was good. None of the MICs for tested isolates were intermediate or resistant, and had they been, it still cannot be concluded that results would have been comparable. However, the disk diffusion and E-test methods have been evaluated in comparison with agar dilution for other Campylobacter species (1, 8, 10) of which resistant or intermediate strains were involved, and results showed a high percentage of agreement in each category for most of the antibiotics. The E test and disk diffusion thus could be acceptable and convenient methods of susceptibility testing when agar dilution cannot be performed.

ACKNOWLEDGMENTS

We thank Manon Lorange from the Laboratoire de Santé Publique du Québec, who graciously provided us with some of the bacterial strains used in this study; Brigite Chevrier and Angela Gurd for secretarial services; and Zeneca Pharma Inc., which contributed to the realization of this project.

FOOTNOTES

    • Received 7 October 1997.
    • Returned for modification 15 January 1998.
    • Accepted 15 April 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Baker C. N.
    The E-Test and Campylobacter jejuni. Diagn. Microbiol. Infect. Dis. 15 1992 469 472
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Blaser M. J.
    Campylobacter and related species Principles and practice in infectious diseases 4th ed. Mandell G. L., Bennett J. A., Dolin R. 1995 1948 1956 Churchill Livingstone New York, N.Y
  3. 3.↵
    1. Butzler J. P.,
    2. Dekeyser P.,
    3. Lafontaine T.
    Susceptibility of related vibrios and Vibrio fetus to twelve antibiotics. Antimicrob. Agents Chemother. 5 1974 86 89
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chow A. W.,
    2. Patten V.,
    3. Bednorz D.
    Susceptibility of Campylobacter fetus to twenty-two antimicrobial agents. Antimicrob. Agents Chemother. 13 1978 416 418
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Edmonds P.,
    2. Patton C. M.,
    3. Barrett T. J.,
    4. Morris G. K.,
    5. Steigerwalt A. G.,
    6. Brenner D. J.
    Biochemical and genetic characteristics of atypical Campylobacter fetus subsp. fetus strains isolated from humans in the United States. J. Clin. Microbiol. 21 1985 936 940
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Fliegelman R. M.,
    2. Petrak R. M.,
    3. Goodman L. J.,
    4. Segreti J.,
    5. Trenholme G. M.,
    6. Kaplan R. L.
    Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species. Antimicrob. Agents Chemother. 27 1985 429 430
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Francioli P.,
    2. Herzstein J.,
    3. Grob J.-P.,
    4. Vallotton J.-J.,
    5. Mombelli G.,
    6. Glauser M. P.
    Campylobacter fetus bacteremia. Arch. Intern. Med. 145 1985 289 292
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Gaudreau C.,
    2. Gilbert H.
    Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter coli. J. Antimicrob. Chemother. 39 1997 707 712
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Goossens H.,
    2. Coignau L. V.,
    3. Butzler J. P.
    In-vitro evaluation of combinations against Campylobacter fetus. J. Antimicrob. Chemother. 24 1989 195 201
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Huang M. B.,
    2. Baker C. N.,
    3. Banerjee S.,
    4. Tenover F. C.
    Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. J. Clin. Microbiol. 30 1992 3243 3248
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Karmali M. A.,
    2. De Grandis S.,
    3. Fleming P. C.
    Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter fetus subsp. fetus to eight cephalosporins with special reference to species differentiation. Antimicrob. Agents Chemother. 18 1980 948 951
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Kwon S.-Y.,
    2. Cho D. H.,
    3. Lee S. Y.,
    4. Lee K.,
    5. Chong Y.
    Antimicrobial susceptibility of Campylobacter fetus subsp. fetus isolated from blood and synovial fluid. Yonsei Med. J. 35 1994 314 319
    OpenUrlPubMed
  13. 13.↵
    1. Lachance N.,
    2. Gaudreau C.,
    3. Lamothe F.,
    4. Turgeon F.
    Susceptibilities of β-lactamase-positive and -negative strains of Campylobacter coli to β-lactam agents. Antimicrob. Agents Chemother. 37 1993 1174 1176
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Lachance N.,
    2. Gaudreau C.,
    3. Lamothe F.,
    4. Larivière L. A.
    Role of β-lactamase of Campylobacter jejuni in resistance to β-lactam agents. Antimicrob. Agents Chemother. 35 1991 813 818
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Meier P. A.,
    2. Dooley D. P.,
    3. Jorgensen J. H.
    Development of quinolone-resistant Campylobacter fetus bacteremia in HIV-infected patients. Clin. Infect. Dis. 17 1993 547
    OpenUrl
  16. 16.↵
    1. Montero A.,
    2. Corbella X.,
    3. Lopez J. A.,
    4. Santin M.,
    5. Ballon I.-H.
    Campylobacter fetus-associated aneurysms: report of a case involving the popliteal artery and review of the literature. Clin. Infect. Dis. 24 1997 1019 1020
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Morooka T.,
    2. Oda T.
    In vitro evaluation of antibiotics for treatment of meningitis caused by Campylobacter fetus subspecies fetus. Pediatr. Infect. Dis. J. 8 1989 653 654
    OpenUrlPubMed
  18. 18.↵
    1. Morrison V. A.,
    2. Lloyd B. K.,
    3. Chia J. K. S.,
    4. Tuazon C. U.
    Cardiovascular and bacteremic manifestations of Campylobacter fetus infection: case report and review. Rev. Infect. Dis. 12 1990 387 392
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Nachamkin I.
    Campylobacter and Arcobacter Manual of clinical microbiology 6th ed. Murray P. R., Baron E. J., Pfaller M. A., Tenover F. C., Yolken R. H. 1995 483 491 American Society for Microbiology Washington, D.C
  20. 20.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 4th ed. Approved standard M7-A4. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  21. 21.↵
    National Committee for Clinical Laboratory Standards Performance standard for antimicrobial disk susceptibility tests 6th ed. Approved standard M2-A6. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  22. 22.↵
    1. Penner J. L.
    The genus Campylobacter: a decade of progress. Clin. Microbiol. Rev. 1 1988 157 172
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Righter J.,
    2. Wells W. A.,
    3. Hart G. D.,
    4. McNeely D. J.
    Relapsing septicemia caused by Campylobacter fetus subsp. fetus. Can. Med. Assoc. J. 128 1983 686 689
    OpenUrlPubMed
  24. 24.↵
    1. Sánchez R.,
    2. Fernández-Baca V.,
    3. Dı́az M. D.,
    4. Muñoz P.,
    5. Rodrı́guez-Créixems M.,
    6. Bouza E.
    Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob. Agents Chemother. 38 1994 1879 1882
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Skirrow M. B.,
    2. Jones D. M.,
    3. Sutcliffe E.,
    4. Benjamin J.
    Campylobacter bacteremia in England and Wales, 1981–91. Epidemiol. Infect. 110 1993 567 573
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Spelhaug D. R.,
    2. Gilchrist M. J. R.,
    3. Washington J. A.
    Bactericidal activity of antibiotics against Campylobacter fetus subspecies intestinalis. J. Infect. Dis. 143 1981 500
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Taylor D. E.,
    2. Courvalin P.
    Mechanisms of antibiotic resistance in Campylobacter species. Antimicrob. Agents Chemother. 32 1988 1107 1112
    OpenUrlFREE Full Text
  28. 28.↵
    1. Taylor D. E.,
    2. Chau A. S.-S.
    Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob. Agents Chemother. 41 1997 665 671
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Taylor D. E.,
    2. Garner R. S.,
    3. Allan B. J.
    Characterization of tetracycline resistance plasmids from Campylobacter jejuni and Campylobacter coli. Antimicrob. Agents Chemother. 24 1983 930 935
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Antimicrobial Susceptibility Testing of 59 Strains of Campylobacter fetus subsp. fetus
Carole Tremblay, Christiane Gaudreau
Antimicrobial Agents and Chemotherapy Jul 1998, 42 (7) 1847-1849; DOI: 10.1128/AAC.42.7.1847

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antimicrobial Susceptibility Testing of 59 Strains of Campylobacter fetus subsp. fetus
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antimicrobial Susceptibility Testing of 59 Strains of Campylobacter fetus subsp. fetus
Carole Tremblay, Christiane Gaudreau
Antimicrobial Agents and Chemotherapy Jul 1998, 42 (7) 1847-1849; DOI: 10.1128/AAC.42.7.1847
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Campylobacter fetus

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596